Company / PP&E (Net)
NovoCure Ltd PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$77.6M
FY2025
5-year range
$22.7M / $77.7M
FY2021-FY2025
Trend
-0.1%
vs FY2024
Sector context
#91 of 135
Health Care
What the data says
At $78M, NovoCure Ltd's pp&e (net) ranks #91 of 135 in the Health Care sector. Improved from $51M to $78M over the past 2 years.
Based on SEC 10-K filings.
$78M in FY2025 with a 5-year CAGR of +46.8%.
Improved from $51M to $78M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +33.4%
- 5-Year CAGR
- +46.8%
- 10-Year CAGR
- -
Sector benchmark
#91 of 135 in Health CareTop 67% of 135This company $77.6M Sector average $1.4B
▼
-94.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +46.8%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 0.1% year-over-year.
- Ranks #91 out of 135 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $77.6M | -0.1% |
| FY2024 | $77.7M | +50.9% |
| FY2023 | $51.5M | +57.5% |
| FY2022 | $32.7M | +44.0% |
| FY2021 | $22.7M | +99.1% |
| FY2020 | $11.4M | +22.0% |
| FY2019 | $9.3M | +10.7% |
| FY2018 | $8.4M | -6.5% |
| FY2017 | $9.0M | -8.0% |
| FY2016 | $9.8M | +49.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026